Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension (2022)
- Authors:
- Autor USP: SOUZA, ROGÉRIO DE - FM
- Unidade: FM
- DOI: 10.1007/s12325-022-02199-x
- Subjects: ESTUDOS RANDOMIZADOS; HIPERTENSÃO PULMONAR; TERAPIA COMBINADA; SOBREVIDA
- Language: Inglês
- Imprenta:
- Source:
- Título: Advances in therapy
- ISSN: 0741-238X
- Volume/Número/Paginação/Ano: v. 39, n. 9, p. 4374-4390, 2022
- Status:
- Artigo aberto em periódico híbrido (Hybrid Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
SOUZA, Rogerio de et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Advances in therapy, v. 39, n. 9, p. 4374-4390, 2022Tradução . . Disponível em: https://doi.org/10.1007/s12325-022-02199-x. Acesso em: 22 abr. 2026. -
APA
Souza, R. de, Delcroix, M., Galie, N., Jansa, P., Mehta, S., Pulido, T., et al. (2022). Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Advances in therapy, 39( 9), 4374-4390. doi:10.1007/s12325-022-02199-x -
NLM
Souza R de, Delcroix M, Galie N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension [Internet]. Advances in therapy. 2022 ; 39( 9): 4374-4390.[citado 2026 abr. 22 ] Available from: https://doi.org/10.1007/s12325-022-02199-x -
Vancouver
Souza R de, Delcroix M, Galie N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension [Internet]. Advances in therapy. 2022 ; 39( 9): 4374-4390.[citado 2026 abr. 22 ] Available from: https://doi.org/10.1007/s12325-022-02199-x - Incidência de hematomas subdurais espontâneos em casos de pacientes com hipertensão arterial pulmonar: Análise de um registro de cinco anos
- Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. [Carta]
- Pulmonary hypertension in sickle cell disease
- Challenging the concept of adding more drugs in pulmonary arterial hypertension [Editorial]
- Pulmonary arterialhHypertension-related morbidity is prognostic for mortality
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
- RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study
- 2016 – Um segundo passo [Editorial]
- Building the Future of Trial Design in PAH on Solid Ground
- Goal-oriented treatment of pulmonary arterial hypertension
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
